GRI Bio R&D Expenses

What does GRI Bio do? GRI Bio, Inc. generates revenue through the development and commercialization of therapies for inflammatory, fibrotic, and autoimmune diseases. The company focuses on advancing a pipeline of Natural Killer T (NKT) modulating therapies, including its lead program GRI-0621, a small molecule RAR-beta dual agonist for Idiopathic pulmonary fibrosis (IPF) treatment. GRI-0621 is formulated as a once-daily oral capsule targeting multiple fibrotic indications. The firm also develops GRI-0803, a novel activator of human Type 2 NKT cells for autoimmune disorders, initially targeting systemic lupus erythematosus. Additionally, GRI Bio holds a library of 500+ proprietary compounds addressing high-value indications with unmet medical needs. GRI Bio's primary customers are pharmaceutical companies and healthcare providers seeking innovative treatments for complex diseases. The company's lead asset GRI-0621 is positioned for clinical development in IPF, while GRI-0803 targets systemic lupus erythematosus. The firm's proprietary compound library supports potential partnerships and licensing agreements for high-value therapeutic areas. The company's business model relies on advancing its pipeline through clinical trials and securing strategic collaborations for drug development and commercialization. The company's revenue streams include potential licensing fees from pharmaceutical partners, milestone payments upon achieving clinical or regulatory milestones, and future royalties from commercialized products. GRI Bio's focus on NKT modulating therapies for inflammatory, fibrotic, and autoimmune diseases positions it to address significant unmet medical needs in these therapeutic areas. The firm's pipeline includes GRI-0621 for IPF and GRI-0803 for systemic lupus erythematosus, with additional compounds targeting other high-value indications. GRI Bio is one of the most popular companies on Eulerpool.